Granulocyte-Colony Stimulating Factor (G-CSF) as Optimizing Therapy for Pediatric Liver Transplantation

Phase

Condition

Diet And Nutrition

Weight Loss

Hepatic Fibrosis

Treatment

N/A

Clinical Study ID

NCT04113317

FakultasKUI

Ages 3-12
All Genders

Study Summary

This study compares the effect of human recombinant Granulocyte-Colony Stimulating Factor (G-CSF) in pediatric patients with liver cirrhosis with a control group. The study aims to observe improvement of (Pediatric End-stage Liver Disease) PELD score and nutritional status prior to liver transplantation procedure. In addition to the intervention, standard treatments for liver cirrhosis are also given for both groups. G-CSF is administered for 12 times.

Condition of disease:

Pediatric patient aged 3 months to 12 years old Liver cirrhosis Undernourished / Severe malnutrition PELD score 10-25

Intervention:

Drug: Recombinant Human G-CSF

Phase:

Phase 3

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age between 3 months to 12 years old
Conscious state
Without the presence of fever (temperature: <37,5°C)
Decompensated liver cirrhosis
Liver cirrhosis due to various etiology
Undernourished or severe malnutrition
PELD score between 10-25

Exclusion

Exclusion Criteria:

Malignancy (liver origin or other types)
History of undergoing any organ transplantation procedure
Acute liver failure
Failure of any organ other than the liver
Encephalopathy
Severe infection such as bacterial peritonitis and pneumonia

Study Design

January 01, 2020

February 28, 2022

Study Description

This open-label randomized control trial conducted in Cipto Mangunkusumo Hospital, Jakarta, Indonesia, aimed to determine the effect of G-CSF to improve PELD score and nutritional status of pediatric patients with liver cirrhosis prior to liver transplantation. A total of 52 pediatric patients with liver cirrhosis, malnutrition and PELD score between 10-25 will be collected and divided into intervention group and control group. The intervention group will be given a subcutaneous injection of G-CSF 5μg/kg/day for 5 days consecutively, followed by a single dose every 3 days up to 12 times throughout the trial. Additionally, both the intervention and control group receive standard liver cirrhosis treatment. Randomization is done using block randomization.

The patients will be clinically monitored and evaluated for anthropometric changes (body weight, mid-arm circumference, mid-arm muscle circumference, and triceps skinfold thickness), complete blood count, absolute neutrophil count, liver function tests, cytokines (IL-10, TNF-α), Procalcitonin, hepatocyte growth factor (HGF), CD34+ cell count and PELD score (albumin, bilirubin, prothrombin and international normalized ratio values).

Data analysis will be performed using IBM SPSS Statistics version 20.0.0.

Connect with a study center

Fakultas Kedokteran Universitas Indonesia
Jakarta, Java 16424
Indonesia
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.